Literatur
- 1 Brenner & Rectors .The
Kidney,. 6th edition, W.B. Saunders Company 2000: 1580-1584
- 2
Brune K, Kalden J, Zacher J. et al. .
Selektive
Inhibitoren der Zyklooxygenase 2. Evolution oder Revolution?.
Dtsch Ärztebl.
2000;
97
A1818-1825
- 3
Crofford L J, Lipsky P E, Brooks P, Abramson S B, Simon L S, Van de Putte L BA.
Basic
biology and clinical application of specific cyclooxygenase-2 inhibitors.
Arthritis
Rheum.
2000;
43
4-13
- 4
Hansson L, Zanchetti A, et al.. HOT
Study Group .
Effects of intensive blood-pressure lowering
and low-dose aspirin in patients with hypertension: principal results
of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet.
1998;
351
1755-1762
- 5
Harris R C.
Cyclooxygenase-2
in the kidney.
J Am Soc Nephrol.
2000;
11
2387-2394
- 6
Henry D, Lim L L, Garcia R L. et al .
Variability
risk of gastrointestinal cmplications with individual non-steroidal
anti-inflammatory drugs: results of a collaborative meta-analysis.
BMJ.
1996;
312
1563-1566
- 7
Izzo J L. et al .
Importance of systolic blood pressure in
older americans.
Hypertension.
2000;
35
1021-1024
- 8
John S, Schmieder R E.
Impaired
endothelial function in arterial hypertension and hypercholesterolemia:
potential mechanisms and differences.
J Hypertens.
2000;
18
363-374
- 9
Johnson A G, Nguyen T V, Day R O.
Do
nonsteroidal anti-inflammatory drugs affect blood pressure?.
Ann
Intern Med.
1994;
121
289-300
- 10
Lipsky P E. and the International COX-2 Study Group .
Analysis
of the effect of COX-2 specific inhibitors and recommendations for
their use in clinical practice.
J Rheumatol.
2000;
27
1338-1340
- 11
London G M, Hornych A, Safar M E, Levenson J A, Simon A C.
Plasma
prostaglandins PGE2 and PGF2a, total effective vascular compliance
and renal plasma flow in essential hypertension.
Nephron.
1982;
32
118-124
- 12
Mukherjee D, Nissen S E, Topol E J.
Risk
of cardiovascular events associated with selective COX-2 inhibitors.
JAMA.
2001;
286
954-959
- 13
Okahara K, Sun B, Kambayashi J.
Upregulation
of prostacyclin synthesis-related gene expression by shear stress
in vascular endothelial cells.
Arterioscler Thromb Vasc
Biol.
1998;
18
1922-1926
- 14
Pope J E. et al .
A meta-analysis of the effects of nonsteroidal
anti-inflammatory drugs on blood pressure.
Arch Intern
Med.
1993;
153
477-484
- 15
Schönbeck U. et al .
Augmented expression of cyclooxygenase-2
in human atherosclerotic lesions.
Am J Pathol.
1999;
155
1281-1291
- 16
Silverstein F E, Faich G, Goldstein J L. et al .
Gastrointestinal toxicity with celecoxib
vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid
arthritis. The CLASS-study.
JAMA.
2000;
284
1247-1255
- 17
Spence J D.
The
arthritic patient with hypertension: selection of an NSAID.
Scand
J Rheumatol Suppl.
1986;
62
36-40
- 18
Stemme V. et al .
Expression of cyclo-oxygenase-2 in humans
atherosclerotic carotid arteries.
Eur J Vasc Endovasc
Surg.
2000;
20
146-152
- 19 The American College of Rheumatology
Clinical Guidelines. Atlanta, Ga: American College
of Rheumatology 1997
- 20
The VIGOR Study Group .
Comparison
of upper gastrointestinal toxicity of rofecoxib and naproxen in
patients with rheumatoid arthritis.
N Engl J Med.
2000;
343
1520-1528
- 21
Thumshirn M, Fried M.
Prophylaxe und Therapie
NSAR-induzierter Ulzera. Ein Update.
Dtsch Med Wochenschr.
2000;
125
975-978
- 22
Whelton A. et al .
Cyclooxygenase-2 specific inhibitors and
cardiorenal function.
Am J Ther.
2001;
8
85-95
- 23
Whelton A, Maurath C J, Verburg K M, Geis G S.
Renal safety
and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.
Am
J Ther.
2000;
7
159-175
- 24
Zollner T M, Ahlbach S, Kaufmann R, Boehrich W -H.
Verträglichkeit
des selektiven Cyclooxygenase-2-Inhibitors Rofecoxib bei Intoleranz
gegenüber nicht steroidalen Antiphlogistika.
Dtsch
Med Wochenschr.
2001;
126
386-388
Korrespondenz
Prof. Dr. R. E. Schmieder
Medizinische Klinik IV/4, Universität
Erlangen-Nürnberg
Krankenhausstraße 12
91054 Erlangen
Phone: 0911/3982702
Fax: 0911/3983183
Email: Roland.Schmieder@rzmail.uni-erlangen.de
